Gossamer Bio Company Description

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States.

The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds.

The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017.

The company was incorporated in 2015 and is headquartered in San Diego, California.

Gossamer Bio, Inc.

Country	United States
Founded	2015
Industry	Biological Products, Except Diagnostic Substances
Employees	145
CEO	Faheem Hasnain

Contact Details

Address: 3115 Merryfield Row San Diego, Delaware 92121 United States
Phone	858 684 1300
Website	gossamerbio.com

Stock Details

Ticker Symbol	4GB
Exchange	Frankfurt Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Faheem Hasnain	Chief Executive Officer
Bryan Giraudo	Chief Financial Officer
Bryan Giraudo	Chief Operating Officer